trans-4-(pyridin-2-yloxy)cyclohexan-1-amine | 412290-10-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-4-(pyridin-2-yloxy)cyclohexan-1-amine
• 英文别名: trans-4-(pyridin-2-yloxy)cyclohexanamine
• CAS: 412290-10-9
• 化学式: C11H16N2O
• InChiKey: RZFKTWPBPUOGIS-MGCOHNPYSA-N

物化性质

• 沸点：
  298.2±30.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.73
• 重原子数：
  14.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  48.14
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  trans-4-(pyridin-2-yloxy)cyclohexan-1-amine 、 3-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)propanoic acid 在 1-丙基磷酸酐 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)-N-(trans-4-(pyridin-2-yloxy)cyclohexyl)propanamide
  参考文献：
  名称：

  Development of Novel Dual Binders as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors

  摘要：

  Tankyrases (TNKS1 and TNKS2) are proteins in the poly ADP-ribose polymerase (PARP) family. They have been shown to directly bind to axin proteins, which negatively regulate the Wnt pathway by promoting β-catenin degradation. Inhibition of tankyrases may offer a novel approach to the treatment of APC-mutant colorectal cancer. Hit compound 8 was identified as an inhibitor of tankyrases through a combination of substructure searching of the Amgen compound collection based on a minimal binding pharmacophore hypothesis and high-throughput screening. Herein we report the structure- and property-based optimization of compound 8 leading to the identification of more potent and selective tankyrase inhibitors 22 and 49 with improved pharmacokinetic properties in rodents, which are well suited as tool compounds for further in vivo validation studies.

  DOI：

  10.1021/jm401317z

文献信息

• Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
  申请人：Madar J. David

  公开号：US20050215784A1

  公开（公告）日：2005-09-29

  The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

  本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖、X综合征、高胰岛素血症、肥胖、动脉粥样硬化和各种免疫调节性疾病。
• [EN] QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF<br/>[FR] COMPOSÉS QUINAZOLINONES ET LEURS DÉRIVÉS
  申请人：AMGEN INC

  公开号：WO2014036022A1

  公开（公告）日：2014-03-06

  Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  公式I的化合物是坦克酶的有用抑制剂。公式I的化合物具有以下结构：其中变量的定义在此提供。
• [EN] OXALAMIDE HETEROBYCYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS OXALAMIDE HÉTÉROBYCYCLIQUES ET COMPOSITIONS POUR LE TRAITEMENT D'AFFECTIONS ASSOCIÉES À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2021067805A1

  公开（公告）日：2021-04-08

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及化学实体（例如，化合物或药用盐，和/或水合物，和/或共晶，和/或化合物的药物组合），其抑制（例如，拮抗）干扰素基因激活器（STING）。所述化学实体可用于治疗条件、疾病或障碍，其中增加（例如，过度）STING激活（例如，STING信号传导）对主体（例如，人类）的病理和/或症状和/或疾病或障碍的进展有贡献。本公开还涉及含有相同化学实体的组合物，以及使用和制备这些组合物的方法。
• Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
  申请人：Madar J. David

  公开号：US20070238753A1

  公开（公告）日：2007-10-11

  The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

  本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，适用于预防或治疗糖尿病，特别是2型糖尿病，以及高血糖、X综合症、高胰岛素血症、肥胖症、动脉硬化和各种免疫调节性疾病。
• PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)
  申请人：Madar J. David

  公开号：US20070265302A1

  公开（公告）日：2007-11-15

  The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

  本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖、X综合征、高胰岛素血症、肥胖症、动脉硬化和各种免疫调节性疾病。